Across TCGA pan-cancer cohorts, PEAK3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PEAK3 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PEAK3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PEAK3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, PDAC, and LSCC are the cancer types where PEAK3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	IV	0.918	0.532	.019	6	view →
PDAC	OS	Quartile	III,IV	0.333	0.984	.024	6	view →
LSCC	DFS	Tertile	All	0.799	0.338	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: PEAK3 tumor-vs-normal RNA expression · all PEAK3 data types